98 related articles for article (PubMed ID: 15124896)
1. Serum concentration of soluble decoy receptor 3 in glioma patients before and after surgery.
Hwang SL; Lin CL; Cheng CY; Lin FA; Lieu AS; Howng SL; Lee KS
Kaohsiung J Med Sci; 2004 Mar; 20(3):124-7. PubMed ID: 15124896
[TBL] [Abstract][Full Text] [Related]
2. Quantification and detection of DcR3, a decoy receptor in TNFR family.
Chen J; Zhang L; Kim S
J Immunol Methods; 2004 Feb; 285(1):63-70. PubMed ID: 14871535
[TBL] [Abstract][Full Text] [Related]
3. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis.
Roth W; Isenmann S; Nakamura M; Platten M; Wick W; Kleihues P; Bähr M; Ohgaki H; Ashkenazi A; Weller M
Cancer Res; 2001 Mar; 61(6):2759-65. PubMed ID: 11289159
[TBL] [Abstract][Full Text] [Related]
4. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer.
Lin WW; Hsieh SL
Biochem Pharmacol; 2011 Apr; 81(7):838-47. PubMed ID: 21295012
[TBL] [Abstract][Full Text] [Related]
5. Functional characterisation of decoy receptor 3 in Crohn's disease.
Funke B; Autschbach F; Kim S; Lasitschka F; Strauch U; Rogler G; Gdynia G; Li L; Gretz N; Macher-Goeppinger S; Sido B; Schirmacher P; Meuer SC; Roth W
Gut; 2009 Apr; 58(4):483-91. PubMed ID: 19039087
[TBL] [Abstract][Full Text] [Related]
6. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT.
Wroblewski VJ; Witcher DR; Becker GW; Davis KA; Dou S; Micanovic R; Newton CM; Noblitt TW; Richardson JM; Song HY; Hale JE
Biochem Pharmacol; 2003 Feb; 65(4):657-67. PubMed ID: 12566095
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia.
Kim S; Fotiadu A; Kotoula V
Clin Immunol; 2005 Jun; 115(3):286-94. PubMed ID: 15893696
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients.
Wu Y; Han B; Sheng H; Lin M; Moore PA; Zhang J; Wu J
Int J Cancer; 2003 Jul; 105(5):724-32. PubMed ID: 12740925
[TBL] [Abstract][Full Text] [Related]
9. Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients.
Otsuki T; Tomokuni A; Sakaguchi H; Aikoh T; Matsuki T; Isozaki Y; Hyodoh F; Ueki H; Kusaka M; Kita S; Ueki A
Clin Exp Immunol; 2000 Feb; 119(2):323-7. PubMed ID: 10632670
[TBL] [Abstract][Full Text] [Related]
10. [Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof].
Shen HW; Wu YL; Peng SY
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):744-7. PubMed ID: 12899749
[TBL] [Abstract][Full Text] [Related]
11. Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma.
Arakawa Y; Tachibana O; Hasegawa M; Miyamori T; Yamashita J; Hayashi Y
Acta Neuropathol; 2005 Mar; 109(3):294-8. PubMed ID: 15627206
[TBL] [Abstract][Full Text] [Related]
12. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action.
Yang CR; Hsieh SL; Teng CM; Ho FM; Su WL; Lin WW
Cancer Res; 2004 Feb; 64(3):1122-9. PubMed ID: 14871847
[TBL] [Abstract][Full Text] [Related]
13. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance.
Connor JP; Felder M
Gynecol Oncol; 2008 Nov; 111(2):330-5. PubMed ID: 18723214
[TBL] [Abstract][Full Text] [Related]
14. Serum decoy receptor 3 is a biomarker for disease severity in nonatopic asthma patients.
Chen MH; Kan HT; Liu CY; Yu WK; Lee SS; Wang JH; Hsieh SL
J Formos Med Assoc; 2017 Jan; 116(1):49-56. PubMed ID: 26911723
[TBL] [Abstract][Full Text] [Related]
15. Modulation of macrophage differentiation and activation by decoy receptor 3.
Chang YC; Hsu TL; Lin HH; Chio CC; Chiu AW; Chen NJ; Lin CH; Hsieh SL
J Leukoc Biol; 2004 Mar; 75(3):486-94. PubMed ID: 14657214
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, metabolic stability, and subcutaneous bioavailability of a genetically engineered analog of DcR3, FLINT [DcR3(R218Q)], in cynomolgus monkeys and mice.
Wroblewski VJ; McCloud C; Davis K; Manetta J; Micanovic R; Witcher DR
Drug Metab Dispos; 2003 Apr; 31(4):502-7. PubMed ID: 12642478
[TBL] [Abstract][Full Text] [Related]
17. High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis.
Bamias G; Kaltsa G; Siakavellas SI; Papaxoinis K; Zampeli E; Michopoulos S; Zouboulis-Vafiadis I; Ladas SD
Clin Immunol; 2010 Nov; 137(2):242-9. PubMed ID: 20675196
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication.
Wu SF; Liu TM; Lin YC; Sytwu HK; Juan HF; Chen ST; Shen KL; Hsi SC; Hsieh SL
J Leukoc Biol; 2004 Feb; 75(2):293-306. PubMed ID: 14634066
[TBL] [Abstract][Full Text] [Related]
19. The glycosaminoglycan-binding domain of decoy receptor 3 is essential for induction of monocyte adhesion.
Chang YC; Chan YH; Jackson DG; Hsieh SL
J Immunol; 2006 Jan; 176(1):173-80. PubMed ID: 16365408
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus.
Lee CS; Hu CY; Tsai HF; Wu CS; Hsieh SL; Liu LC; Hsu PN
Clin Exp Immunol; 2008 Mar; 151(3):383-90. PubMed ID: 18190609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
